← Eichor
Condition: Locally Advanced Unresectable Or Metastatic Solid Tumors Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Locally Advanced Unresectable Or Metastatic Solid Tumors

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
Phase 1/Phase 2 · 2 location(s) · RemeGen Co., Ltd. · NCT05205850A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
Phase 1 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06493864A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic
Phase 1/Phase 2 · 31 location(s) · RemeGen Co., Ltd. · NCT06016062BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Phase 1 · 1 location(s) · Innovent Biologics (Suzhou) Co. Ltd. · NCT06418061A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Phase 1/Phase 2 · 26 location(s) · Frontier Medicines Corporation · NCT06244771Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors
Phase 1 · 9 location(s) · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · NCT06963281Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer
Phase 1/Phase 2 · 14 location(s) · Salubris Biotherapeutics Inc · NCT06667960A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works
Phase 1/Phase 2 · 11 location(s) · Regeneron Pharmaceuticals · NCT06413680A Phase 1 Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors
Phase 1 · 8 location(s) · NEOK Bio, Inc. · NCT07612176A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor
Phase 1/Phase 2 · 10 location(s) · A2 Biotherapeutics Inc. · NCT06682793A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
Phase 1 · 2 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT05470348Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients Wi
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06364410A Study of TAK-505 in Adults With Solid Tumors
Phase 1/Phase 2 · 15 location(s) · Takeda · NCT07436728Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The Co
Phase 2 · 483 location(s) · National Cancer Institute (NCI) · NCT05564377A Study of AP601 in Patients With Locally Unresectable Advanced or Metastatic Solid Tumors
Phase 1 · 3 location(s) · AP Biosciences Inc. · NCT07165067A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecul
Phase 1/Phase 2 · 8 location(s) · Marengo Therapeutics, Inc. · NCT06827613AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 3 location(s) · Avelos Therapeutics Inc. · NCT06911333A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer
Phase 1/Phase 2 · 2 location(s) · Spago Nanomedical AB · NCT06184035Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
Phase 2 · 30 location(s) · BeiGene · NCT03736889Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Neg
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT05098210A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Phase 1/Phase 2 · 7 location(s) · Astellas Pharma Global Development, Inc. · NCT07287995(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Phase 3 · 126 location(s) · Cogent Biosciences, Inc. · NCT05208047GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
Phase 1/Phase 2 · 4 location(s) · GeneMedicine Co., Ltd. · NCT06265025IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors
Phase 1 · 5 location(s) · Innovent Biologics (Suzhou) Co. Ltd. · NCT06349408IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 3 location(s) · Innovent Biologics (Suzhou) Co. Ltd. · NCT06974812Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors
Phase 1 · 1 location(s) · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · NCT07589205A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors
Phase 1/Phase 2 · 6 location(s) · Innovent Biologics (Suzhou) Co. Ltd. · NCT05636215A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors
Phase 1/Phase 2 · 39 location(s) · RemeGen Co., Ltd. · NCT07105215SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors
Phase 2 · 1 location(s) · Shenyang Sunshine Pharmaceutical Co., LTD. · NCT07646626
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.